Share on StockTwits

Shares of Medidata Solutions (NASDAQ:MDSO) have been given a consensus rating of “Buy” by the fourteen brokerages that are covering the stock, American Banking & Market News reports. Three research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $58.37.

Several analysts have recently commented on the stock. Analysts at Stifel Nicolaus raised their price target on shares of Medidata Solutions from $47.00 to $55.00 in a research note on Thursday. Separately, analysts at Topeka Capital Markets reiterated a “buy” rating on shares of Medidata Solutions in a research note on Wednesday. They now have a $50.00 price target on the stock, up previously from $49.00. Finally, analysts at Jefferies Group raised their price target on shares of Medidata Solutions from $50.00 to $53.00 in a research note on Wednesday. They now have a “buy” rating on the stock.

Shares of Medidata Solutions (NASDAQ:MDSO) opened at 43.86 on Wednesday. Medidata Solutions has a 52-week low of $32.10 and a 52-week high of $68.21. The stock has a 50-day moving average of $41.53 and a 200-day moving average of $48.96. The company has a market cap of $2.301 billion and a price-to-earnings ratio of 367.54.

Medidata Solutions (NASDAQ:MDSO) last released its earnings data on Tuesday, July 29th. The company reported $0.17 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.18 by $0.01. The company had revenue of $83.20 million for the quarter, compared to the consensus estimate of $81.90 million. During the same quarter last year, the company posted $0.36 earnings per share. Medidata Solutions’s revenue was up 22.2% compared to the same quarter last year. Analysts expect that Medidata Solutions will post $0.76 EPS for the current fiscal year.

Medidata Solutions, Inc (NASDAQ:MDSO) is a global provider of software-as-a-service (SaaS), clinical technology solutions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.